Of note, a prospective randomized trial in oesophageal cancer (with subgroup analysis by histological subtype) (NCT00525200), which will aim to determine if p53 mutation has a predictive role in response to three different types of NA-C, which will be randomly assigned, has recently completed recruitment. Here, TP53 is linked to carcinoma of esophagus.